Elastic NV vs Cassava Sciences Inc — how do they compare? Elastic NV trades at $61.97 (market cap $6.47B), while Cassava Sciences Inc trades at $1.06 (market cap $53.14M). The key difference: Elastic NV is far larger — about 121.8× Cassava Sciences Inc's market cap, and Elastic NV is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ESTC | FLNA | |
|---|---|---|
Market Cap | $6.47B | $53.14M |
Sector | Technology | Health |
52-Week High | $94.47 | $4.64 |
52-Week Low | $43.30 | $1.09 |
Enterprise Value | $5.69B | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $62.84, up 0.83% on the day, with a bullish technical signal from moving averages. The company shows strong profitability metrics with a 76.07% gross margin and 21.14% net margin, though current earnings show a net loss. Recent news highlights Elastic Security achieving a 100% malware protection score (Business Wire, July 15, 2026), while multiple law firm investigations create headline risk.
The outlook is mixed: analyst consensus is strongly bullish with a $73 price target and no sell ratings, but high EV/EBITDA (164.13) suggests premium valuation. Key opportunities include consistent earnings beats and leadership in security markets, while risks include ongoing legal investigations and the transition to profitability from current net losses.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Latest headlines on both assets
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →